Today Stories
Byondis B.V., an independent, clinical stage biopharmaceutical company creating precision medicines, and Glycotope, a biotechnology company developing antibodies against proteins carrying tumor-specific carbohydrate structures, have entered into a platform access agreement to discover and develop antibodies that target specific tumor-associated protein/carbohydrate combined glyco-epitopes (GlycoTargets).
Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs). Specific financial terms have not been disclosed.
“Selective tumor targeting is key to maximize the potential of our linker-drug platfo…
Translational Science Center for the Healthcare business sector to offer flexible ways of working coupled with the latest technology and equipment
New Learning Center will bring all vocational training occupations together under one roof
Both construction projects meet the highest sustainability requirements
Merck, a leading science and technology company, plans to invest € 270 million at its global headquarters in Darmstadt by building a new Translational Science Center for its Healthcare business sector as well as a new Learning Center. The two construction projects are part of the € 1 billion investment package that Merck announced in March 2019 and plans to realize in Darmstadt by 2025.
“Darmstadt is our site of the future. With these investments, we are underscoring the strategic im…
Bachem is pleased to announce that the company has been recognised as one of the five winners of the Swiss Biotech Success Stories Awards 2021. They have been recognised for the value that they have consistently achieved for the past 50 years — a success story based on quality, innovation, sustainability and technological leadership. The company has grown over 50% in the last five years — operating with sites across the world — and now offer more than 5,500 different biologically active peptides, amino acid derivatives and oligonucleotides.
The prestigious awards, bestowed by the Swiss Biotech Association, celebrate those who have made important and sustainable contributions to the biotech industry in Switzerland. Selected success stories such as Bachem are showcased to illustrate how Sw…
The company employs real-world data and evidence to accelerate research through targeted site and patient recruitment strategies
Based on its recent analysis of the global clinical research organization (CRO) market, Frost & Sullivan recognizes leading global CRO Parexel with the 2021 Global Enabling Technology Leadership Award. Parexel streamlines clients’ clinical development programs, enabling them to navigate market, regulatory, and patient access-related challenges seamlessly. Leveraging a leading suite of end-to-end biopharmaceutical development services covering patient-focused clinical trial design and decentralized clinical trial (DCT) strategies, the company has helped develop 198 of the 200 top-selling biopharmaceuticals in the market.
“Parexel employs a dedicated project t…
UK, 19th July 2021 – The Advanced Therapy Treatment Centre (ATTC) network, London Advanced Therapies (LAT) and the Cell and Gene Therapy Catapult (CGTC), in partnership with Health Education England elearning for healthcare, have developed a new eLearning programme targeted at healthcare and academic professionals to support their learning on both the fundamentals and clinical adoption of advanced therapies.
This series of eLearning sessions is designed to give the learner a core understanding of advanced therapies, how they function in the body, and the steps involved in delivering these medicines. The modules take the learner from the basics of cell and gene therapy, through to a more in-depth look at products currently being delivered through both commissioned treatments and clinical tr…
Plan aims to unlock up to £400 million of new private investment and create up to 5,000 new highly-skilled jobs over next decade
Stevenage could become one of Europe’s largest ‘clusters’ for biotechnology and other early-stage life science companies
Vision for campus developed in partnership with Stevenage Bioscience Catalyst, UK Government and Stevenage Borough Council; GSK to make 33 acres of land available for development at the company’s R&D site in Stevenage
GSK has today announced that it has formally started the process of seeking a development partner to transform land within the company’s existing 92-acre Research & Development site in Stevenage into one of Europe’s largest ‘clusters’ for biotechnology and other early-stage life science companies.
The vision for the new…
Eli Lilly and Company (NYSE: LLY) today announced the acquisition of Protomer Technologies ("Protomer"), a private biotech company. Protomer's proprietary peptide- and protein-engineering platform is used to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity.
The potential value of the transaction is over $1 billion, with successful achievement of future development and commercial milestones. Lilly previously led an equity investment in Protomer alongside the JDRF T1D Fund, providing Lilly with 14 percent ownership of the company. Lilly is acquiring the remainder of the stock of Protomer beyond its initial investment.
Founded in 2015 and based in Pasadena, California, Protomer is engineering next-generation protein therapeutics tha…
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of its collaboration with My Green Lab, a non-profit organization committed to improving the environmental sustainability of scientific research. The company has set a goal to obtain Accountability, Consistency and Transparency (ACT) labelling for its entire cold temperature storage portfolio by the end of 2021. Over time, Thermo Fisher expects to ACT label more than 1,200 additional SKUs, enabling research, pharmaceutical and clinical laboratories to achieve their sustainability objectives by providing a broader range of purchasing options.
"Our customers are committed to adopting more sustainable laboratory practices, and My Green Lab enables them to take proactive steps to meet th…
Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars , including 100 million dollars in upfront and near-term clinical milestone payments
Novo Nordisk will develop the phase 2 ready antibody PRX004 for the rare heart disease ATTR cardiomyopathy
Prothena Corporation plc and Novo Nordisk A/S today announced that the companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme.
PRX004 is a phase 2ready anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associated with the disease pathology of ATTR amyloidosis.
ATTR amyloidosis is a rare, progressive and fatal disease characterised by the abn…
Thermo Fisher Scientific, the world leader in serving science, today announced a collaboration with Ortho Clinical Diagnostics to promote and distribute Thermo Scientific MAS Quality Controls and LabLink xL Quality Assurance Software for use with Ortho Clinical Diagnostics VITROS analyzers.
Through this agreement, Ortho Clinical Diagnostics customers will have complete access to MAS third-party quality controls as well as the LabLink xL web-based quality assurance program that provides real-time quality control monitoring with automatic data entry upload and audit-friendly reports. Customers will also have access to additional features, including support, service and quality control ranges for specific reagent lots, unique features that are not currently available through any other quality…
The EMPEROR-Preserved Phase III trial met its primary endpoint and demonstrated significant risk reduction with empagliflozin for the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction (HFpEF)
HFpEF has been classified as “the single largest unmet need in cardiovascular medicine”1 based on prevalence, poor outcomes and the absence of clinically proven therapies to date2
With approval, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of heart failure patients regardless of ejection fraction
The EMPEROR-Preserved Phase III trial met its primary endpoint, establishing empagliflozin as the first and only thera…
Alzheimer’s Research UK has been selected as the official 2021 charity partner of Hertfordshire-based company, Innovative Trials.
The company, which specialises in clinical trial patient recruitment and community engagement, is aiming to raise at least £5,000 for the charity over the next 12 months. The funds raised will support groundbreaking dementia research for a world free from the fear, harm, and heartbreak of dementia.
In the UK, almost one million people are thought to be living with dementia and this is expected to rise to two million by 2050. Alzheimer’s Research UK is the UK’s leading dementia research charity committed to developing life-changing treatments and cures - a mission shared by Innovative Trials.
Kate Shaw, founder and CEO of Innovative Trials, said: “Dementia is a…
BioMed X Institute expands its collaboration with Merck KGaA, Darmstadt, Germany to a total of eight research programs.
Call for application of the new research program ‘Extrachromosomal DNA in Cancer’ to open now.
Heidelberg, Germany, July 5, 2021 – BioMed X, a leading independent research institute, announced today the start of its eighth joint research program with Merck KGaA, Darmstadt, Germany. The new program will explore the role of extrachromosomal DNA in cancer and it will complement the research of two ongoing oncology programs at BioMed X in the fields of DNA damage response and RNA splicing.
Extrachromosomal circular DNA (ecDNA) was recently found to be particularly abundant in multiple human cancer cells, although its frequency varies among different cancer types. Elevated l…
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a leading contract development and manufacturing organization (CDMO), today confirmed that following the European Medicines Agency’s (EMA) Committee for Human Medicines (CHMP) approval of the Recipharm Monts site on June 11, 2021, drug product manufacture of the Moderna COVID-19 vaccine at the site in France has now begun.
“We are proud to be working with Recipharm to build industrial production capacity in France in support of Europe’s vaccination campaign,” said Stephane Bancel, Chief Executive Officer of Moderna. “France is at the heart of European innovation in healthcare and will play an important role in Moderna’s strategic growth plan.”
“Our c…
Publication comes alongside new ABPI Principles to help companies operate to high ethical standards
The Association of the British Pharmaceutical Industry (ABPI) 2021 Code of Practice comes into force from 1 July, alongside new ABPI Principles to help companies operate to high ethical standards.
The ABPI Code of Practice is the industry’s commitment to operate in a professional, ethical, and transparent manner, for the benefit of patients and the public. It is independently administered by the Prescription Medicines Code of Practice Authority (PMCPA).
The 2021 Code has been updated to make the Code easier for companies to use in their day-to-day activities, to reflect changes in the environment companies operate in and to reflect updates to the European Code.
Some new elements increase…
Approximately €400million investment annually to accelerate end-to-end R&D of next-generation vaccines, fully financed through resource reallocation
Focus on innovating mRNA vaccines beyond pandemic to routine use in diseases with high unmet need
Expected minimum of six clinical candidates by 2025
PARIS – June 29, 2021 - Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. The Center will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and chemistry, manufacturing and controls (CMC) teams across sites at Cambridge, MA (US) and Marcy l’Etoile, Lyon (France). …
As part of Sanofi’s ongoing efforts to reduce the complexity of its Consumer Healthcare portfolio and accelerate its growth trajectory, the company has signed an agreement with STADA for the divestiture of 16 Consumer Healthcare products commercialized in Europe. The transaction with STADA ensures that these products will continue to be available to consumers.
"As discussed during our Capital Markets Day in February, simplifying the CHC product portfolio is an important part of our strategy to focus our resources and efforts where we can bring the most value, especially to consumers. We are pleased these products will continue to be available for consumers as we focus on becoming a fully integrated standalone business” said Julie Van Ongevalle, Executive Vice-President, Sanofi and Head of…
Leonard Award program recognizes innovation and positive achievements in the diabetes community
Lilly to give $100,000 to Life for a Child in recognition of five Award winners
In honor of the 100th anniversary of the discovery of insulin, Eli Lilly and Company (NYSE: LLY) today launched the Leonard Award to recognize diverse champions dedicated to advancing diabetes management through innovative thinking and novel approaches. Nominations are being accepted now until August 31, 2021 at Lilly.com/LeonardAward.
The Leonard Award is inspired by the life of Leonard Thompson, the first person with diabetes to be treated with insulin in 1922, and looks to celebrate ongoing achievements in the diabetes community. The Award is open to eligible participants from the following categories:
Teen/yo…
Aleta Biotherapeutics (‘Aleta’) and Cancer Research UK today announced a collaboration to advance the early phase clinical development of Aleta’s CAR-T cell engagercandidate, ALETA-001.
Aleta is a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, and Cancer Research UK is the world’s leading cancer charity dedicated to saving lives.
Under the terms of the clinical development partnership, Cancer Research UK’s Centre for Drug Development will fund, sponsor and conduct the first-in-human Phase 1/2a clinical trial of ALETA-001, which will be led by Dr Amit Patel’s Cellular and CAR-T therapies team at The Christie NHS Foundation Trust in Manchester, UK.
ALETA-001 has been developed to benefit peo…
Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise
Positive preclinical safety and immunogenicity data for mRNA influenza vaccine candidates support initiation of Phase 1 clinical trial
Interim data anticipated by the end of 2021; outcomes from this clinical trial will inform next steps of our mRNA-based influenza vaccine program and strategy
Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza.
The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate co…
